当前位置：
X-MOL 学术
›
Clin. Colorectal Cancer
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Cost-Effectiveness of the New Combination Trifluridine/Tipiracil Plus Bevacizumab for the Third-Line Treatment for Metastatic Colorectal Cancer in Italy
Clinical Colorectal Cancer ( IF 3.4 ) Pub Date : 2023-10-14 , DOI: 10.1016/j.clcc.2023.10.005 Jacopo Giuliani 1 , Beatrice Mantoan 2 , Daniela Mangiola 1 , Marco Muraro 1 , Giuseppe Napoli 1 , Marina Tommasi 3 , Francesco Fiorica 1 , Marta Mandarà 1
Clinical Colorectal Cancer ( IF 3.4 ) Pub Date : 2023-10-14 , DOI: 10.1016/j.clcc.2023.10.005 Jacopo Giuliani 1 , Beatrice Mantoan 2 , Daniela Mangiola 1 , Marco Muraro 1 , Giuseppe Napoli 1 , Marina Tommasi 3 , Francesco Fiorica 1 , Marta Mandarà 1
Affiliation
Abstract not available
中文翻译：
意大利三氟尿苷/替吡西加贝伐单抗新组合用于转移性结直肠癌三线治疗的成本效益
摘要不可用
更新日期：2023-10-14
中文翻译：
意大利三氟尿苷/替吡西加贝伐单抗新组合用于转移性结直肠癌三线治疗的成本效益
摘要不可用
京公网安备 11010802027423号